Affiliation:
1. Department of Urinary Surgery, The People’s Hospital of Qingyang City, Qingyang, China
2. Department of Clinical Laboratory Medicine, The People’s Hospital of Qingyang City, Qingyang, China
3. Department of Neurosurgery, The People’s Hospital of Qingyang City, Qingyang, China
4. Department of Clinical Laboratory Medicine, The Hospital of TCM of Gansu Province, Lanzhou, China
5. Department of Cardiology, The People’s Hospital of Qingyang City, Qingyang, China.
Abstract
We analyzed the polymorphisms of 7 antihypertensive drugs-related genes and the factors associated with hypertension in hypertensive patients of Han ethnicity in Qingyang, China. A total of 354 hypertensive patients of Han ethnicity were enrolled from Qingyang, China. The ACE (I/D), ADRB1 (1165G > C), AGTR1 (1166A > C), CYP2C9*3, CYP2D6*10, CYP3A5*3 and NPPA (T2238C) polymorphisms were assessed. Clinical data of patients was also obtained. The influencing factors of hypertension were evaluated. The genotype frequencies of ACE, ADRB1, AGTR1, CYP2C9, CYP3A5 and NPPA loci were in Hardy-Weinberg equilibrium, with mutation frequencies of 39.27%, 74.29%, 6.21%, 4.80%, 72.46% and 0.71%, respectively. CYP2D6 locus was not in Hardy-Weinberg equilibrium. There was no statistical difference in allele frequencies between different genders (P > .05). There was significant difference in the frequencies of ACE (I/D) and NPPA (T2238C) loci among different regions of China (P < .05). Gender, ACE (I/D) and ADRB1 (1165G > C) gene polymorphism, smoking, homocysteine and HDL levels were associated hypertension. The mutation frequencies of ADRB1 (1165G > C) and CYP3A5*3 were high in hypertensive patients of Han ethnicity in Qingyang, suggesting these patients may be more sensitive to beta-blockers and calcium ion antagonists. Meanwhile, hypertension was associated with gender, ACE (I/D) and ADRB1 (1165G > C) gene polymorphisms, smoking, homocysteine and HDL levels.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference32 articles.
1. 2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia network.;Kario;J Clin Hypertens (Greenwich),2020
2. Mobile health applications for the management of primary hypertension: a multicenter, randomized, controlled trial.;Gong;Medicine (Baltim),2020
3. 2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension.;J Geriatr Cardiol,2019
4. Advances in the treatment strategies in hypertension: present and future.;Verdecchia;J Cardiovasc Dev Dis,2022
5. The future of pharmacogenetics in the treatment of hypertension.;Cunningham;Pharmacogenomics,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献